Under terms of the agreement announced June 21, Arrowhead will conduct all activities through preclinical stages of development of the drug. Horizon will receive a worldwide exclusive license to the drug and will be wholly responsible for clinical development and commercialization.
“We believe Horizon’s expertise in the clinical development and commercialization of therapies for gout makes them an ideal partner,” Christopher Anzalone, Arrowhead’s chief executive, said in the announcement. “This collaboration with Horizon also represents further expansion of our rapidly growing pipeline of investigational RNAi therapeutics.”
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Arrowhead Strikes Major Partnership With Takeda
- Arrowhead Shares Plunge After Drug Trial Is Halted
- Arrowhead Pharmaceuticals Cuts Deal With J&J Valued at Up to $3.7B
- Arrowhead Hits the Mark
- Arrowhead Pharmaceuticals Inc.
- Licensing Deals Pay Off for Arrowhead, Xencor
- Arrowhead’s Liver Drug Shows Early Promise
- Arrowhead Shares Surge on Big Pharma Acquisition, Positive Earnings